Together, the accumulated data show that it is possible for mitochondria to become resistant to BIM- but not cBID-induced release of cytochrome c. The activation of mechanisms that prevent BIM from causing mitochondrial cytochrome c release is a previously un-appreciated way for cancer cells to acquire resistance to oncogene-targeted therapies. The gene discussed is CYCS; the disease is cancer.